To describe and compare healthcare resource utilization (HRU) and healthcare costs in patients treated with CDK4/6 inhibitors in real-world clinical practice
Latest Information Update: 25 Jan 2021
At a glance
- Drugs Abemaciclib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Jan 2021 New trial record
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium